Berni has been working in biomedical research since 2004 and started employment at Swansea University as a health economist in 2009. Since then she has been involved in over 20 projects as Principal Investigator or lead health economist with collaborators across the UK and Europe.
Her main focus of work in recent years has been on cancer treatment, nosocomial infections, chronic pain and health technology assessment.
Recently completed work includes leading the health economic modelling undertaken to estimate the cost-effectiveness of stem cell transplantation and to inform guidance as recently published in NICE guidance NG52 (management of non-Hodgkin’s Lymphoma); lead health economist in modelling cost-effectiveness of new interventions in the treatment of chronic pain and lead health economist in the analysis of cost-effectiveness of a risk scoring tool in primary care.
Berni is the SCHE team leader for the health economic assessment of new medicines submitted to the All Wales Therapeutic and Toxicology Centre (AWTTC) as part of the review undertaken by the New Medicines Group and All Wales Medicines Strategy Group (AWMSG).